Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study-Reference-Cited by-同舟云学术

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

Published:2021-05-06 Issue:11 Volume:134 Page:1299-1309
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Shi Yuan-Kai,Hong Xiao-Nan,Yang Jian-Liang,Xu Wei,Huang Hui-Qiang,Xiao Xiu-Bin,Zhu Jun,Zhou Dao-Bin,Han Xiao-Hong,Wu Jian-Qiu,Zhang Ming-Zhi,Jin Jie,Ke Xiao-Yan,Li Wei,Wu De-Pei,Yang Shen-Miao,Du Xin,Jia Yong-Qian,Liu Ai-Chun,Liu Dai-Hong,Shen Zhi-Xiang,Zhang Lian-Sheng,James Leonard,Hellriegel Edward

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference22 articles.

1. Global patterns and trends in the incidence of non-Hodgkin lymphoma;Miranda-Filho;Cancer Causes Control,2019

2. How I treat indolent lymphoma;Gribben;Blood,2007

3. The clinical course of follicular lymphoma;Rohatiner;Best Pract Res Clin Haematol,2005

4. Non-Hodgkin lymphoma;Shankland;Lancet,2012

5. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity;Leoni;Semin Hematol,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022);Holistic Integrative Oncology;2023-11-27

2. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

3. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China;Computational and Mathematical Methods in Medicine;2022-01-20

4. Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial;Investigational New Drugs;2022-01-15